Enhertu Partial Change Approval
Trastuzumab deruxtecan (genetical recombination)
Approval Information
Brand NameEnhertu
Partial Change Approval
Generic NameTrastuzumab deruxtecan (genetical recombination)
ApprovedSeptember 2020
TypeInitial Approval
Review Reports
Want structured data, translation summaries & alerts?
PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.
Join the WaitlistSource: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.